Skip to main content

Table 1 The baseline characteristics in the nafamostat mesilate and the control groups

From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis

 

Nafmostat mesilate (n = 201)

Control (n = 149)

Total (N = 350)

P value

Age, y, median (range)

68 (55–75)

66 (54–74)

66 (55–75)

0.436

Male (%)

74 (36.8)

59 (39.6)

133 (38.0%)

0.596

History of AP (%)

3 (1.5)

0

3 (0.9%)

 

SOD (%)

2 (1.0)

0

2 (0.6%)

 

Purpose of ERCP (%)

 Choledocholithiasis

120 (59.7)

81 (54.4)

201 (57.4%)

0.318

 Malignant biliary stricture

67 (33.3)

56 (37.6)

123 (35.1%)

0.410

 Benign biliary stricture

11 (5.5)

8 (5.4)

19 (5.4%)

0.966

 Biliary leakage

0

1 (0.7)

1 (0.3%)

 

 Pancreatic cyst

1 (0.5)

2 (1.3)

3 (0.9%)

0.577

 Other indicationa

2 (1.0)*

1 (0.7)

3 (0.9%)

0.745

Procedures (%)

 Difficult cannulation

115 (57.2)

59 (39.6)

174 (49.7%)

0.001

 P-duct manipulation

69 (34.3)

44 (29.5)

113 (32.3%)

0.342

 Precut EST

70 (34.8)

42 (28.2)

112 (32.0%)

0.188

 Pancreatic EST

44 (21.9)

20 (13.4)

64 (18.3%)

0.043

 EPBD

21 (10.4%)

18 (12.1%)

39 (11.1%)

0.631

 ERPD

43 (21.4%)

20 (13.4%)

63 (18.0%)

0.055

  1. AP acute pancreatitis, SOD sphincter of Oddi dysfunction, ERCP endoscopic retrograde cholangiopancreatography, P-duct pancreatic duct, EST endoscopic sphincterotomy, EPBD endoscopic papillary balloon dilatation, ERPD endoscopic retrograde pancreatic drainage
  2. aIntraductal papillary neoplasm of bile duct, Mirrizi’s syndrome